Please use this identifier to cite or link to this item: http://nopr.niscpr.res.in/handle/123456789/35512
Title: New visible spectrophometric methods for the assay of cintapride
Authors: Kannajosyula, Murali Krishna
Amperayani, Karteek Rao
Parimi, Uma Devi
Keywords: Cinitapride (CIN);Visible spectrophotometry;Metol-Cr (VI);DMPD–CAT;NBS/Br-/metol–SA;EDDP/KIO3
Issue Date: Sep-2016
Publisher: NISCAIR-CSIR, India
Abstract: In this study, four new simple, accurate and highly sensitive spectrophotometric methods have been developed for the determination of Cinitapride (CIN), in both pure and in pharmaceutical preparations. The method M1 [Metol-Cr (VI)] and M2 (DMPD – CAT) are direct methods. The method M3 (NBS/Br-/metol - SA) where the drug is oxidised with excess of N-bromosuccunimide in acid medium, followed by the determination of unreacted N-bromosuccunimide with the dye Celestin Blue and M4 (EDDP/KIO3), where the coloured species formation appears to be due to the formation of coloured charge-transfer complex are indirect methods. Regresion analysis of Beer’s law plots show good correlation in the concentration range of 4.0-16, 2.0-12.0, 4.0-14 and 2-10 µg/mL for methods M1, M2, M3 and M4 respectively, and the corresponding molar absorptivity values are 0.6741 × 104, 3.3708 × 104, 2.5155 × 104 and 2.435×104 L mol-1cm-1. All variables have been optimized and the results were statistically compared with those of literature methods by employing the student’s T-test and F-test. No interference has been observed from excipients normally added to the tablets. All the methods are new and superior to the existing methods in terms of λ max and molar absorpitivity. The methods can be applied to the routine pharmaceutical analysis of cinitapride in the formulations.
Page(s): 425-432
ISSN: 0975-0991 (Online); 0971-457X (Print)
Appears in Collections:IJCT Vol.23(5) [September 2016]

Files in This Item:
File Description SizeFormat 
IJCT 23(5) 425-432.pdf209.13 kBAdobe PDFView/Open


Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.